Back to bills
Most Favored Patient Act of 2026 — HR. 7837
Last updated: 3/5/2026 · Introduced: 3/5/2026
Author: Daniel Meuser (R-PA)
TL;DR (AI)
- This bill requires the Center for Medicare and Medicaid Innovation to test a model implementing most-favored-nation drug pricing for covered drugs.
- Under this model, manufacturers must provide access to the second-lowest net price of a drug in a set of reference countries and report pricing information to the Secretary.
- The model will be in effect for five years, and may be suspended if a manufacturer agrees to provide most-favored-nation pricing and increase manufacturing operations in the United States.
Verified Votes
No verified votes yet.
Community Votes
No community votes yet. Be the first!
Voting as guest · Sign in for verified votes
Other Sections
Includes provisions on preamble, short title., and 1 more.
3 sections
Click "Show details" to explore individual sections. Use the community vote above or visit All Sections to vote per section.
Want the full experience?
Create a free account to cast verified votes on each section, get a personalized summary, and track your voting history.
Create Free Account